Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells

(2020) Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells. Eur J Pharmacol. p. 172883. ISSN 1879-0712 (Electronic) 0014-2999 (Linking)

Full text not available from this repository.

Abstract

Glucosamine (GlcN), a natural amino sugar in human body, was reported to exhibit anticancer activity against some tumors. In the present study, we evaluated the cytotoxicity and multi-drug resistance (MDR) reversal activity of GlcN on resistant MRP2-overexpressing ovarian cancer A2780RCIS cells. The cytotoxicity and MDR reversal activity of GlcN on cancer cells were measured by MTT assay. The effects of GlcN on MRP1 and MRP2 mRNA expression and function were evaluated by qRT-PCR and flow cytometry, respectively. The cell migration capacity of ovarian cancer cells were assessed in the presence or absence of GlcN using wound healing migration assay. Furthermore, the effects of GlcN on the mRNA expression of E-cadherin, vimentin and alpha-smooth muscle actin as Epithelial-Mesenchymal Transition (EMT)-related markers were evaluated by qRT-PCR. Our results indicated that glucosamine reduced the proliferation of human ovarian cancer cell lines (A2780) and its cisplatin resistant variant (A2780RCIS) in a dose-dependent manner. The IC50 values for A2780RCIS cells treated with cisplatin in the presence of different concentrations of GlcN (0, 1, 2 and 3 mM) for 72 h were 44.463 +/- 1.603, 35.17 +/- 0.025, 22.25 +/- 0.018, 17.78 +/- 0.012 muM respectively. Also GlcN decreased the expression of MRP1 and MRP2 mRNA in ovarian cancer cells. Our results further demonstrated that although GlcN had no significant effects on the expression of studied EMT-related markers in invasive A2780RCIS cells, it was able to inhibit their migration in vitro. According to these findings, GlcN could effectively enhance cisplatin cytotoxicity in resistant A2780RCIS cells.

Item Type: Article
Keywords: Cisplatin (CIS) Epithelial-mesenchymal transition (EMT) Glucosamine (GlcN) Multidrug resistance-associated protein 2 (MRP2) Ovarian cancer
Subjects: QV Pharmacology
QZ Pathology > QZ 200-380 Neoplasms
Divisions: Faculty of Pharmacy and Pharmaceutical Sciences > Department of Clinical Biochemistry
Page Range: p. 172883
Journal or Publication Title: Eur J Pharmacol
Journal Index: Pubmed, ISI
Volume: 868
Identification Number: https://doi.org/10.1016/j.ejphar.2019.172883
ISSN: 1879-0712 (Electronic) 0014-2999 (Linking)
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/11815

Actions (login required)

View Item View Item